Prodia Group's Transformation to Build a Holistic Healthcare Ecosystem in Indonesia

Jakarta - Prodia Group, through its three subsidiaries, PT Prodia Widyahusada Tbk (Prodia/PRDA), PT Prodia Diagnostic Line (Proline), and PT Prodia StemCell Indonesia (ProSTEM), continues its efforts to build a holistic healthcare ecosystem in Indonesia.

In 2024, Prodia recorded various achievements demonstrating sustainable growth and innovation. One example is the development of the digital application "U by Prodia," equipped with the latest features. These include the Smart Report 2.0 feature and the Health Plan, designed to be personalized and evidence-based for customers.

Prodia Founder and President Commissioner Andi Widjaja stated that digitalization has been one of PRDA's promises since its stock exchange listing in 2016. "Back when we went public in 2016, I said that Prodia's rules were to embrace next-generation medicine," Andi said at the "Prodia Connect: Insight and Networking" event at The Grand Mansion, Central Jakarta, Tuesday (February 18, 2025).

The 'U by Prodia' app provides a better digital health experience. Launched in March 2023, the platform has already attracted 1.4 million downloads.

In addition, Prodia also acquired a 39% stake in ProLine, a well-known Indonesian manufacturer of in vitro diagnostic medical devices. This acquisition further strengthens the relationship and synergy between the two entities in supporting the Indonesian healthcare ecosystem.

"When PRDA purchased ProLine's shares at the time, the funds were used to purchase this machine. This significantly increased its capacity," said Andi.

ProLine itself produces various Domestic Medical Device (DMD) products, including clinical chemistry reagents, urine strips, molecular products, immunology products, instruments, rapid diagnostic tests, in vitro diagnostic (IVD) instruments, and IV spare parts, providing a complete solution for the healthcare industry. Furthermore, ProLine's Domestic Component Level (TKDN) score of 40% supports the government's vision.

"The quality has been proven, and it is available at an affordable price," said Andi.

Furthermore, following the acquisition of Prodia, ProLine is building a second factory on a 5,500m2 site with a building area of ​​9,690m2, which will triple production capacity. The second factory, located in Cikarang, West Java, is scheduled to open in April 2025.

"ProLine can also serve 4,800 of the 10,416 community health centers (Puskesmas), which is expected to improve equitable access to quality healthcare services," Andi explained.

Another innovation developed by the Prodia Group is ProSTEM. ProSTEM is a laboratory for the storage, processing, and development of clinical applications for stem cells and their metabolites.

"We are collaborating with universities and BRIN (National Research and Innovation Agency) to develop products. ProSTEM has a permit from the government (Ministry of Health), Good Manufacturing Practices for Drugs/Drug Ingredients (CPOB) certification from the National Agency of Drug and Food Control (BPOM), and ISO 9001:2015 quality assurance," Andi said.

By 2024, ProSTEM had successfully developed cell therapy for difficult-to-treat treatments. Andi hopes this synergy will support the development of an ecosystem within the Indonesian healthcare industry.

"With this synergy, Prodia is also committed to expanding its ProLine distribution network, establishing more collaborations with hospitals, healthcare facilities, and related agencies, and supporting the development of the latest technologies in the healthcare industry," Andi explained.

For your information, the Prodia Connect: Insight and Networking event carried the theme "Welcoming Future Health Innovation: The Potential of the Medical Device Industry, Regenerative Medicine, and Laboratory Diagnostics in Indonesia." In addition to Andi, Prodia President Director Dewi Muliaty and ProSTEM Director Cynthia Retna Sartika also served as speakers.